Your search returned 2 results.

Results
	1.	Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. [electronic resource] by Friedberg, Jonathan W Mahadevan, Daruka Cebula, Erin Persky, Daniel Lossos, Izidore Agarwal, Amit B Jung, Jungah Burack, Richard Zhou, Xiaofei Leonard, E Jane Fingert, Howard Danaee, Hadi Bernstein, Steven H Producer: 20140228 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 32 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. [electronic resource] by Holkova, Beata Kmieciak, Maciej Bose, Prithviraj Yazbeck, Victor Y Barr, Paul M Tombes, Mary Beth Shrader, Ellen Weir-Wiggins, Caryn Rollins, April D Cebula, Erin M Pierce, Emily Herr, Megan Sankala, Heidi Hogan, Kevin T Wan, Wen Feng, Changyong Peterson, Derick R Fisher, Richard I Grant, Steven Friedberg, Jonathan W Producer: 20161213 In: Leukemia & lymphoma vol. 57 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search